Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Deloitte
Farmers Insurance
Accenture
Citi
McKesson
Colorcon
Teva

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIGECYCLINE

« Back to Dashboard

Clinical Trials for Tigecycline

Trial ID Title Status Sponsor Phase Summary
NCT00079885 Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the study will be the clinical response in the clinically evaluable population and the clinical response in the clinical modified intent-to-treat population at the TOC visit. The primary efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If tigecycline is found to be noninferior, the analyses will determine whether tigecycline is statistically better than levofloxacin.
NCT00079976 Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
NCT00079989 Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.
NCT00080496 Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
NCT00081575 Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.
NCT00081744 Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tigecycline

Condition Name

Condition Name for Tigecycline
Intervention Trials
Cross Infection 4
Skin Diseases, Infectious 3
Bacterial Pneumonia 3
Intra-abdominal Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tigecycline
Intervention Trials
Infection 29
Communicable Diseases 23
Intraabdominal Infections 14
Pneumonia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tigecycline

Trials by Country

Trials by Country for Tigecycline
Location Trials
United States 116
China 27
Canada 15
Argentina 13
Korea, Republic of 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tigecycline
Location Trials
California 9
Florida 7
Ohio 7
Pennsylvania 6
Georgia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tigecycline

Clinical Trial Phase

Clinical Trial Phase for Tigecycline
Clinical Trial Phase Trials
Phase 4 13
Phase 3 17
Phase 2/Phase 3 3
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tigecycline
Clinical Trial Phase Trials
Completed 32
Recruiting 4
Withdrawn 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tigecycline

Sponsor Name

Sponsor Name for Tigecycline
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 23
Pfizer 10
University of California, San Diego 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tigecycline
Sponsor Trials
Industry 37
Other 25
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
McKesson
Teva
Farmers Insurance
Chinese Patent Office
Deloitte
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.